WO2001032616A3 - Derives d'oxetanone - Google Patents

Derives d'oxetanone Download PDF

Info

Publication number
WO2001032616A3
WO2001032616A3 PCT/US2000/029641 US0029641W WO0132616A3 WO 2001032616 A3 WO2001032616 A3 WO 2001032616A3 US 0029641 W US0029641 W US 0029641W WO 0132616 A3 WO0132616 A3 WO 0132616A3
Authority
WO
WIPO (PCT)
Prior art keywords
compounds
producing
derivatives
oxetanone
processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/029641
Other languages
English (en)
Other versions
WO2001032616A2 (fr
Inventor
John Jason Gentry Mullins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/431,551 external-priority patent/US6235305B1/en
Priority to IL14404500A priority Critical patent/IL144045A0/xx
Priority to EP00973938A priority patent/EP1144377A4/fr
Priority to JP2001534769A priority patent/JP2003524685A/ja
Priority to CA002358921A priority patent/CA2358921A1/fr
Priority to KR1020017008352A priority patent/KR20010108059A/ko
Application filed by Individual filed Critical Individual
Priority to AU12381/01A priority patent/AU1238101A/en
Priority to MXPA01006755A priority patent/MXPA01006755A/es
Publication of WO2001032616A2 publication Critical patent/WO2001032616A2/fr
Priority to US09/901,166 priority patent/US20020016307A1/en
Publication of WO2001032616A3 publication Critical patent/WO2001032616A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
    • C07D305/02—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D305/10—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having one or more double bonds between ring members or between ring members and non-ring members
    • C07D305/12—Beta-lactones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

Cette invention a trait à de nouveaux composés à base de dérivé d'oxétanone ainsi qu'à des procédés de production de ces dérivés qui se révèlent des plus utiles en tant qu'inhibiteurs de la lipase. Elle porte également sur des procédés de production de sels et de compositions pharmaceutiques ainsi que de composés renfermant au moins ce dérivé d'oxétanone ou ce sel. Elle concerne, de surcroît, des techniques d'utilisation de ces composés et compositions aux fins de l'inhibition des lipases.
PCT/US2000/029641 1999-10-27 2000-10-27 Derives d'oxetanone Ceased WO2001032616A2 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
MXPA01006755A MXPA01006755A (es) 1999-10-29 2000-10-27 Derivados de la oxetanona.
EP00973938A EP1144377A4 (fr) 1999-10-29 2000-10-27 Derives d'oxetanone
JP2001534769A JP2003524685A (ja) 1999-10-29 2000-10-27 オキセタノン誘導体
CA002358921A CA2358921A1 (fr) 1999-10-29 2000-10-27 Derives d'oxetanone
KR1020017008352A KR20010108059A (ko) 1999-10-29 2000-10-27 옥세타논 유도체
IL14404500A IL144045A0 (en) 1999-10-29 2000-10-27 Oxetanone derivatives
AU12381/01A AU1238101A (en) 1999-10-29 2000-10-27 Oxetanone derivatives
US09/901,166 US20020016307A1 (en) 1999-10-27 2001-07-09 Pharmaceutical composition with both a lipase inhibitor and a lipophilic polysaccharide and an improved method for treating adiposity

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US09/431,551 US6235305B1 (en) 1999-10-29 1999-10-29 Essentially nonabsorbable lipase inhibitor derivatives, pharmaceutical compositions and methods of use therefor
US09/431,551 1999-10-29
US16596099P 1999-11-17 1999-11-17
US06/165,960 1999-11-17
US61832800A 2000-07-18 2000-07-18
US09/618,328 2000-07-18

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US61832800A Continuation-In-Part 1999-10-27 2000-07-18

Publications (2)

Publication Number Publication Date
WO2001032616A2 WO2001032616A2 (fr) 2001-05-10
WO2001032616A3 true WO2001032616A3 (fr) 2002-01-10

Family

ID=27389199

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2000/029641 Ceased WO2001032616A2 (fr) 1999-10-27 2000-10-27 Derives d'oxetanone
PCT/US2000/029592 Ceased WO2001032670A1 (fr) 1999-10-29 2000-10-27 Dérivés d'oxétanone

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US2000/029592 Ceased WO2001032670A1 (fr) 1999-10-29 2000-10-27 Dérivés d'oxétanone

Country Status (8)

Country Link
EP (1) EP1144377A4 (fr)
JP (1) JP2003524685A (fr)
CN (1) CN1342169A (fr)
AU (2) AU1347701A (fr)
CA (1) CA2358921A1 (fr)
IL (1) IL144045A0 (fr)
MX (1) MXPA01006755A (fr)
WO (2) WO2001032616A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
US6730319B2 (en) 2001-06-06 2004-05-04 Hoffmann-La Roche Inc. Pharmaceutical compositions having depressed melting points
DE102004009076A1 (de) * 2004-02-23 2005-10-27 Solvay Pharmaceuticals Gmbh Alkylcarbamat-substituierte β-Lactone, Verfahren und Zwischenprodukte zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US7074822B2 (en) 2004-02-23 2006-07-11 Solvay Pharmaceuticals Gmbh Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189438A (en) * 1977-02-08 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active substance esterastin
US4202824A (en) * 1978-05-25 1980-05-13 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active derivatives of esterastin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5246960A (en) * 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
CA1328881C (fr) * 1984-12-21 1994-04-26 Pierre Barbier Procede pour la fabrication d'oxetanones
CA1270837A (fr) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
IL97148A (en) * 1990-02-26 1996-11-14 Hoffmann La Roche Oxetanones a process for their manufacture and pharmaceutical compositions containing them
CA2128044C (fr) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Compositions pharmaceutiques comportant un glucosidase et/ou un inhibiteur d'amylase, et un inhibiteur des lipases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4189438A (en) * 1977-02-08 1980-02-19 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active substance esterastin
US4202824A (en) * 1978-05-25 1980-05-13 Zaidan Hojin Biseibutsu Kagaku Kenkyu Kai Physiologically active derivatives of esterastin

Also Published As

Publication number Publication date
JP2003524685A (ja) 2003-08-19
CN1342169A (zh) 2002-03-27
AU1238101A (en) 2001-05-14
AU1347701A (en) 2001-05-14
CA2358921A1 (fr) 2001-05-10
MXPA01006755A (es) 2003-05-15
WO2001032670A1 (fr) 2001-05-10
EP1144377A1 (fr) 2001-10-17
EP1144377A4 (fr) 2002-05-02
WO2001032616A2 (fr) 2001-05-10
IL144045A0 (en) 2002-04-21

Similar Documents

Publication Publication Date Title
WO2002076976A3 (fr) Inhibiteurs de rho-kinase
WO2002076977A3 (fr) Inhibiteurs de rho-kinase
MY134136A (en) Novel compounds comprising jak3 kinase inhibitors
WO1999043651A3 (fr) Inhibiteurs d'enzymes phospholipases
CA2367017A1 (fr) Inhibiteurs de l'enzyme impdh
WO2000043373A3 (fr) Inhibiteurs de kinase
GEP20094847B (en) Novel phenyl-propargylether derivatives
WO2008049105A3 (fr) Dérivés contenant un sulfamoyle et leurs utilisations
WO2003048081A3 (fr) Glycinamides en tant qu'inhibiteurs du facteur xa
GB0401088D0 (en) Phosphoramidate derivatives
WO2003057145A3 (fr) 4,9-dihydrocyclopenta[imn]phenanthridine-5-ones substitues, leurs derives et leurs utilisations
HK1053107A1 (zh) 作为jnk抗化剂的pyrazoloanthrone及其衍生物和它们的成份
WO2007059230A3 (fr) 1h-benzimidazole-4-carboxamides substitues efficaces en tant qu’inhibiteurs de parp
MXPA03001463A (es) Derivados de benzofurano o benzotiofeno de aminoalquilbenzoil, metodo para preparar los mismos y composiciones que los contienen.
WO2004009091A8 (fr) Agonistes des recepteurs x du foie
WO2004032908A3 (fr) Methode d'inhibition de l'angiogenese
WO2000000198A8 (fr) Derives de piperidine agissant sur les systemes lies a la serotonine
WO2006121719A3 (fr) Inhibiteurs de l'epoxyde hydrolase soluble et leurs methodes d'utilisation
WO2002016340A8 (fr) Aminoalkoxybenzoyl-benzofuranes ou benzothiophenes, leur procede de preparation et les compositions les contenant
WO2003007883A3 (fr) Acylsemicarbazides inhibiteurs de kinase dependant de la cycline utiles en tant qu'agents anticancereux et antiproliferatifs
WO2004021988A3 (fr) Traitement de la douleur par inhibition de la map kinase p38
WO2001087287A3 (fr) Composes actifs sur le plan pharmaceutiques et procedes d'utilisation
WO2000040232A3 (fr) Nouvelles compositions et trousses de bretylium, et leur utilisation dans la prevention et le traitement des pathologies cardio-vasculaires
WO2004073375A3 (fr) Derives de podophyllotoxine utiles comme agents antitumoraux
WO2008065485A3 (fr) Compositions pharmaceutiques stables composées d'un bloqueur des canaux calcium et d'un inhibiteur ace

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 00804391.4

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2358921

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 144045

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2001 534769

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006755

Country of ref document: MX

Ref document number: 1020017008352

Country of ref document: KR

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2000973938

Country of ref document: EP

Ref document number: 12381/01

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000973938

Country of ref document: EP

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

ENP Entry into the national phase

Ref document number: 2358921

Country of ref document: CA

WWW Wipo information: withdrawn in national office

Ref document number: 2000973938

Country of ref document: EP